KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Non-Current Assets (2017 - 2026)

Amneal Pharmaceuticals has reported Non-Current Assets over the past 9 years, most recently at $1.8 billion for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 7.66% year-over-year to $1.8 billion; the TTM value through Dec 2025 reached $7.2 billion, down 9.3%, while the annual FY2025 figure was $1.8 billion, 7.66% down from the prior year.
  • Non-Current Assets for Q4 2025 was $1.8 billion at Amneal Pharmaceuticals, roughly flat from $1.8 billion in the prior quarter.
  • Over five years, Non-Current Assets peaked at $2.5 billion in Q1 2022 and troughed at $1.8 billion in Q3 2025.
  • A 5-year average of $2.2 billion and a median of $2.3 billion in 2023 define the central range for Non-Current Assets.
  • Biggest five-year swings in Non-Current Assets: grew 4.12% in 2022 and later decreased 12.7% in 2024.
  • Year by year, Non-Current Assets stood at $2.4 billion in 2021, then decreased by 1.32% to $2.4 billion in 2022, then decreased by 12.26% to $2.1 billion in 2023, then dropped by 8.64% to $1.9 billion in 2024, then dropped by 7.66% to $1.8 billion in 2025.
  • Business Quant data shows Non-Current Assets for AMRX at $1.8 billion in Q4 2025, $1.8 billion in Q3 2025, and $1.8 billion in Q2 2025.